Perioperative anticoagulation in patients with mechanical heart valves undergoing elective surgery: results of a survey conducted among Korean physicians.
The optimal perioperative anticoagulation management in patients on warfarin therapy is poorly defined due to the lack of randomized trials. Because guidelines are heterogeneous, it was hypothesized that "treatment strategies are not uniform in clinical practice". Between February 2003 and May 2003, a questionnaire with 4 different clinical scenarios was distributed to physicians by e-mail, or direct contact was made by a survey monitor. Two scenarios described the cases of patients with a mechanical heart valve (MHV) in the mitral position, with additional risk factors for a systemic embolism; one undergoing major (scenario 1) and the other minor surgery (scenario 3). Two scenarios described patients with an aortic MHV; one undergoing major (scenario 2) and the other minor (scenario 4) surgery. Different preoperative and postoperative management options were offered. The treatment options for all scenarios were the same. Of the 90 questionnaires distributed, 52 (57.8%) were returned. Hospitalization for full-dose intravenous unfractionated heparin (IV UH) was the most commonly selected strategy in the preoperative phase for scenarios 1 (59%), 2 (42%) and 3 (44%). In scenario 4, 34% chose IV UH. Outpatient, full- dose, subcutaneous UH or low-molecular-weight heparin (LMWH) was the most selected option in the postoperative phase for all scenarios, with the exception of number 4 (52.9% in scenario 1, 34% in scenario 2, 32%, in scenario 3 and 28% in scenario 4). Even among expert clinicians, the management of perioperative anticoagulation is heterogeneous. In particular, the definition of risk categories and the optimal intensity of antithrombotic drugs need to be defined by well-designed prospective studies.
Oh
Doyeun
D
Department of Internal Medicine, College of Medicine, Pochon CHA University, 351 Yatap-dong, Bundang-gu, Sungnam, Kyunggi-do 463-712, Korea. doh@cha.ac.kr
Kim
Sehyun
S
Lim
Chang Young
CY
Lee
Jong Seok
JS
Park
Seonyang
S
Garcia
David
D
Crowther
Mark A
MA
Ageno
Walter
W
D000925:Anticoagulants / Q000627:therapeutic use*; D019538:Health Care Surveys; D006350:Heart Valve Prosthesis; D006801:Humans; D007723:Korea / Q000453:epidemiology; D019990:Perioperative Care / Q000379:methods*; D010820:Physicians; D012307:Risk Factors; D013927:Thrombosis / Q000453:epidemiology / Q000517:prevention & control*; D014859:Warfarin / Q000627:therapeutic use*
D000925:Anticoagulants; D014859:Warfarin
Heart. 2003 May;89(5):527-30
12695457
Am J Cardiol. 1999 Aug 15;84(4):478-80, A10
10468095
Chest. 1999 Nov;116(5):1240-6
10559081
Semin Thromb Hemost. 1998;24 Suppl 1:77-83
9840696
Arch Intern Med. 2000 Jan 24;160(2):181-8
10647756
Chest. 2001 Jan;119(1 Suppl):220S-227S
11157651
Thromb Res. 2002 Oct 1;108(1):3-13
12586125
J Thorac Cardiovasc Surg. 1994 Apr;107(4):1136-45
8159036
N Engl J Med. 1997 May 22;336(21):1506-11
9154771
Ann Thorac Surg. 1996 Mar;61(3):806-13
8619697
Chest. 2001 Jan;119(1 Suppl):22S-38S
11157641
Circulation. 1998 Nov 3;98(18):1949-84
9799219
J Thromb Haemost. 2006 Jun;4(6):1246-52
16706967
Circulation. 1996 Nov 1;94(9):2107-12
8901659